- Home
- HHS vs SCNX Comparison
HHS vs SCNX Comparison
Compare HHS & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.31
HOLD
Current Price
$0.24
Company Overview
Basic Information| Metric | HHS | SCNX |
|---|---|---|
| Founded | 1923 | 2010 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Advertising | Other Pharmaceuticals |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 19.0M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | HHS | SCNX |
|---|---|---|
| Price | $2.31 | $0.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 3.1K | ★ 2.3M |
| Earning Date | 03-17-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $159,570,000.00 | N/A |
| Revenue This Year | N/A | $347.88 |
| Revenue Next Year | N/A | $744.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.23 | $0.37 |
| 52 Week High | $5.39 | $2.60 |
Technical Indicators
Market Signals| Indicator | HHS | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 28.54 | 25.52 |
| Support Level | N/A | N/A |
| Resistance Level | $3.03 | $0.58 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 16.07 | 0.28 |
Price Performance
Historical Comparison HHS
SCNX
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.